Fresenius Kabi has tapped pharmaceuticals distribution company medac to amplify sales of its pegfilgrastim biosimilar in Germany.
Fresenius Kabi, which earlier this week announced a biosimilar application filing with the FDA, said it has signed an agreement with medac, a Wedel, Germany—based pharmaceuticals company, to market the adalimumab biosimilar Idacio in Germany, which is where it was originally launched in 2019. Adalimumab is used for the treatment of plaque psoriasis, ankylosing spondylitis, Crohn disease, and ulcerative colitis.
Based in Bad Homburg, Germany, Fresenius Kabi has a broad slate of pharmaceutical products and announced on Wednesday that the FDA had accepted for review its biologics license application for the pegfilgrastim candidate MSB11455, which references Neulasta. Pegfilgrastim stimulates the growth of infection-fighting cells, and oncologists use it to treat febrile neutropenia, which results from chemotherapy.
Medac specializes in products for the diagnosis and treatment of oncological, urological, and autoimmune diseeases. Frensenius Kabi said in a statement today that the companies had agreed to cooperate on serving the market for rheumatological care in Germany, utilizing medac’s sales distribution network.
Fresenius Kabi said that the partnership has sales potential because medac provides methotrexate for the parenteral treatment of patients with chronic inflammatory diseases, and methotrexate is often paired with adalimumab as a treatment regimen.
“The partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting,” Fresenius Kabi said in its statement.
Pegfilgrastim MSB11455
The FDA application for a pegfilgrastim biosimilar marks Fresenius Kabi’s first biosimilar regulatory submission for the US market. It has other plans for biosimilar launches in the United States, having already announced in 2019 that it had reached an agreement with AbbVie, the maker of reference adalimumab, to market Idacio in the United States in 2023.
AbbVie’s adalimumab (Humira) notched sales of $19.1 billion in 2019. It faces a field of multiple competitor biosimilars in 2023. Neulasta earned Amgen $665 million in 2019.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.